A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies, Followed by an Expansion in Subjects With Measurable Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Sapanisertib (Primary)
- Indications Bladder cancer; Endometrial cancer; Renal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 30 Jan 2018 Planned End Date changed from 1 Dec 2017 to 30 Jun 2018.
- 31 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 03 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.